Status:
COMPLETED
A Study In Patients With Advanced Solid Tumor
Lead Sponsor:
Pfizer
Conditions:
Neoplasms
Eligibility:
All Genders
20+ years
Phase:
PHASE1
Brief Summary
This study designed to evaluate the pharmacokinetics and safety of AG-013736 at single doses and multiple doses
Eligibility Criteria
Inclusion
- Patients histologically or cytologically diagnosed with advanced solid tumors
- Patients for whom standard therapies have not been effective, or for whom there are no suitable therapies
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2
- Patients with no uncontrolled hypertension
Exclusion
- Patients who have central lung lesions involving major blood vessels
- Patients who require anticoagulant therapy.
- Patients with active epilepsy seizure or symptoms, with brain metastases requiring treatment, with spinal cord compression and with carcinomatous meningitis.
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2010
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00726752
Start Date
July 1 2008
End Date
April 1 2010
Last Update
May 23 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Kobe, Hyōgo, Japan